NCT01266083 2024-11-19WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)Sellas Life Sciences GroupPhase 2 Completed22 enrolled 8 charts